In the latest venture in the emerging field of psychedelics, Google co-founder Sergey Brin is funding the research and development of a hallucinogen sourced from a rainforest shrub for potential use as a mental health treatment.
The non-profit investment vehicle Catalyst4, which was established with the funds from Brin’s 2021 sale of his Tesla interest, has agreed to contribute approximately $15 million of a $25 million funding round for the psychedelic start-up Soneira, according to multiple individuals who were informed of the conversations. According to the biotech, clinical trials investigating ibogaine, a shrub native to west Africa, as a potential treatment for traumatic brain injury (TBI) are about to begin.
Because of its mind-altering properties, Gabonese communities who live in forests have long utilised ibogaine as part of their spiritual rites. In recent years, psychedelic enthusiasts in the West and mental health academics have been more interested in this drug.
This year, ibogaine therapy was found to improve mental health symptoms and cognitive function in thirty US military veterans with traumatic brain injury (TBI). The research was supported by Brin’s philanthropic foundation and conducted at Stanford University.
Soneira is investigating ways to combine ibogaine with heart drugs to reduce the danger of deadly cardiac arrhythmia associated with the plant. Nolan Williams, a psychiatrist at Stanford University who worked on the study, is advising Soneira on this project.
According to the folks, it is also working on creating a synthetic form of the substance. With the money, Soneira intends to start early-stage clinical trials. The newest illustration of Silicon Valley’s passion for psychedelics as an investment and for personal usage comes from Brin’s vehicle, which was founded in 2021. With proceeds from the $366 million profit from Brin’s selling of his whole Tesla investment, Catalyst4 was established.
Continuing, Elon Musk, the founder of Tesla, has openly discussed his use of ketamine as a depression treatment. Billionaire tech investor Peter Thiel was among the first investors in Atai Life Sciences, a biotech company that is investigating ibogaine as a treatment for opioid use disorder in addition to psychedelic-based mental health treatments.
The digital news media reports that based on statistics from PitchBook, venture investors have invested around $180 million in psychedelic biotechs so far this year. With $528 million raised, the sector saw record-breaking investment in 2021.
The Google co-founder has contributed hundreds of millions of dollars to the study of neurological and psychological disorders through the Sergey Brin Family Foundation.
Forbes lists Brin as the ninth richest person in the world. In 2004, Brin learned that he had a genetic mutation that increased his likelihood of developing Parkinson’s disease.
According to a request for tax-exempt status with the Internal Revenue Service, Catalyst4, which had $430 million in total assets at the end of 2022, is mandated to invest in cutting-edge cures for neurological illnesses and technology to counteract climate change. Bayshore Global Management, one of the largest family offices in the world with assets of at least $100 billion, employs one member of the Catalyst4 board of directors.
The people indicated that roughly six other parties have also had conversations regarding investing in Soneira. These include digital health start-up investor LifeForce Capital and Helena Special Investments, the impact investor behind Lykos Therapeutics, which is awaiting a regulatory ruling regarding the use of MDMA as a treatment for post-traumatic stress disorder. The funding phase for Soneira will end after the summer.
However, Helena and Soneira choose not to comment. Requests for comments from LifeForce and Catalyst4 were not answered.
